Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Major Challenges in Providing an Effective and Timely Pandemic Vaccine for Influenza A(H7N9)

Major Challenges in Providing an Effective and Timely Pandemic Vaccine for Influenza A(H7N9) VIEWPOINT ONLINE FIRST Major Challenges in Providing an Effective and Timely Pandemic Vaccine for Influenza A(H7N9) 60%-93%). In a study of unadjuvanted A(H1N1)pdm09 vac- Michael T. Osterholm, PhD, MPH cine conducted in the United States, effectiveness was 56% Katie S. Ballering, PhD (95% CI, 23%-75%). For these studies, most participants Nicholas S. Kelley, PhD were younger than 50 years, with approximately half younger than 18 years. There is no reason to believe that a yet-to-be-developed HE EMERGENCE OF AVIAN INFLUENZA A(H7N9) VI- pandemic A(H7N9) vaccine will perform any better than ex- rus in humans has public health authorities around isting seasonal vaccines or the A(H1N1)pdm09 vaccines, par- the world on high alert for the potential develop- ticularly with regard to vaccine efficacy in persons older than Tment of a human influenza pandemic. As of May 65 years. To date, the median age of H7N9 cases is 60 years. 8, 2013, authorities had identified 131 confirmed cases and If a pandemic occurs and this epidemiologic pattern per- 32 deaths among residents of 8 provinces and 2 munici- sists, a pandemic A(H7N9) vaccine, even if it includes an palities in China. adjuvant, will likely have limited to modest effects on the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Major Challenges in Providing an Effective and Timely Pandemic Vaccine for Influenza A(H7N9)

JAMA , Volume 309 (24) – Jun 26, 2013

Loading next page...
 
/lp/american-medical-association/major-challenges-in-providing-an-effective-and-timely-pandemic-vaccine-x2hlklBPPk
Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2013.6589
pmid
23700117
Publisher site
See Article on Publisher Site

Abstract

VIEWPOINT ONLINE FIRST Major Challenges in Providing an Effective and Timely Pandemic Vaccine for Influenza A(H7N9) 60%-93%). In a study of unadjuvanted A(H1N1)pdm09 vac- Michael T. Osterholm, PhD, MPH cine conducted in the United States, effectiveness was 56% Katie S. Ballering, PhD (95% CI, 23%-75%). For these studies, most participants Nicholas S. Kelley, PhD were younger than 50 years, with approximately half younger than 18 years. There is no reason to believe that a yet-to-be-developed HE EMERGENCE OF AVIAN INFLUENZA A(H7N9) VI- pandemic A(H7N9) vaccine will perform any better than ex- rus in humans has public health authorities around isting seasonal vaccines or the A(H1N1)pdm09 vaccines, par- the world on high alert for the potential develop- ticularly with regard to vaccine efficacy in persons older than Tment of a human influenza pandemic. As of May 65 years. To date, the median age of H7N9 cases is 60 years. 8, 2013, authorities had identified 131 confirmed cases and If a pandemic occurs and this epidemiologic pattern per- 32 deaths among residents of 8 provinces and 2 munici- sists, a pandemic A(H7N9) vaccine, even if it includes an palities in China. adjuvant, will likely have limited to modest effects on the

Journal

JAMAAmerican Medical Association

Published: Jun 26, 2013

References